Company Nymox Pharmaceutical Corporation
Equities
NYMXF
BSP733981026
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3 USD | 0.00% | 0.00% | -49.15% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Patrick Doody
BRD | Director/Board Member | - | 23-07-11 |
Director/Board Member | - | 23-03-20 | |
Suresh Kalbag
PRN | Corporate Officer/Principal | - | - |
General Counsel | - | 20-02-05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 06-06-07 |
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Director/Board Member | 88 | 15-06-30 | |
Director/Board Member | - | 23-03-20 | |
Patrick Doody
BRD | Director/Board Member | - | 23-07-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 93,265,000 | 54,049,529 ( 57.95 %) | 0 | 57.95 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
-49.15% | 28.01M | |
+3.13% | 43.43B | |
+48.60% | 41.69B | |
+8.49% | 41.31B | |
-10.82% | 27.14B | |
+8.26% | 25.28B | |
-23.69% | 18.47B | |
+1.58% | 12.33B | |
+32.83% | 12.59B | |
+6.63% | 11.03B |
- Stock Market
- Equities
- NYMXF Stock
- Company Nymox Pharmaceutical Corporation